Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, including roles at Bristol Myers Squibb, Karuna Therapeutics and AbbVie. His appointment is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
The appointment comes as Helus Pharma aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
Dr. Kramer's expertise in medical affairs is expected to be instrumental as the company progresses its clinical programs and engages with the medical community. For more details, the full press release is available at https://ibn.fm/FdEXH.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma is a trademark of Cybin Corp.
